ExpreS2ion’s U.S. partner Integrated BioTherapeutics launches first ExpreS2-based research product
ExpreS2ion Biotech Holding AB’s fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) has initiated sales and marketing of its first ExpreS2-based product. The product, an Ebola virus glycoprotein, is marketed as a part of IBT’s high-quality research protein portfolio and can be used in the development of diagnostic or therapeutic products.ExpreS2ion stated in July 2017 that the Company will receive a two-digit percentage royalty based on net sales of ExpreS2-based products that IBT will